Lake Forest, CA — October 2025 — The United States Patent and Trademark Office (USPTO) has officially granted patents covering Biodynamik’s breakthrough technologies for tissue distraction and automation. This milestone underscores Biodynamik’s commitment to advancing regenerative limb salvage through innovative, patented technologies.

These newly issued patents secure Biodynamik’s exclusive rights to its core systems that enable precise, automated tissue distraction to promote biological regeneration. Under U.S. patent law, the grants provide Biodynamik with the right to exclude others from making, using, or selling these patented technologies throughout the United States, ensuring strong protection for its intellectual property portfolio.

The patented systems form the foundation of Biodynamik’s XT3 and AT3 platforms, which drive controlled mechanical stimulation to improve circulation and accelerate natural healing in patients with chronic or ischemic wounds.

“These patents validate the engineering and development that have gone into creating our platform,” said Johnny Chen, Founder and CEO of Biodynamik. “They strengthen our ability to bring these technologies to more patients worldwide, while continuing to advance safer, smarter, and more effective approaches to limb salvage.”

This achievement marks a significant step in Biodynamik’s mission to revolutionize diabetic limb care and regenerative healing through innovation, precision engineering, and a relentless focus on improving patient outcomes.